The safety of valsartan: Results of a postmarketing surveillance study on 12 881 patients in England

Journal of Human Hypertension

Volumn 16, Issue 11, 2002, Pages 795-803

  Biswas, Pipasha N ^a   Wilton, L V ^a   Shakir, S W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Adverse drug reactions; Prescription event monitoring; Safety; Valsartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENDROFLUMETHIAZIDE; IBUPROFEN; VALSARTAN; WARFARIN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLEEDING; BLEEDING DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVAL HEMORRHAGE; COUGHING; DATA BASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; EJACULATION DISORDER; EPISTAXIS; FACE EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; GENERAL PRACTITIONER; GINGIVA BLEEDING; HEADACHE; HEART FAILURE; HEART PALPITATION; HEARTBURN; HEMATURIA; HEMOPTYSIS; HEPATITIS; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; IMPOTENCE; INCIDENCE; INDIGESTION; INSOMNIA; ISCHEMIC HEART DISEASE; LASSITUDE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRENATAL DRUG EXPOSURE; PRESCRIPTION; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; RETINA HEMORRHAGE; SIDE EFFECT; TASTE DISORDER; THORAX PAIN; UNITED KINGDOM; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DIZZINESS; DRUG MONITORING; ENGLAND; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; NAUSEA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY OUTCOME; PRODUCT SURVEILLANCE, POSTMARKETING; SUPPORT, NON-U.S. GOV'T; TETRAZOLES; VALINE;

EID: 0036866158     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001490     Document Type: Article

References (18)

1. Rawlins MD, Jefferys DB. United Kingdom product license applications involving new active substances, 1987-1989: Their fate after appeals. Br J Clin Pharmacol 1993; 35: 599-602.
2. Ramsay LE, Yeo WW. ACE inhibitors, angiotension II antagonists and cough. J Hum Hypertens 1995; 9(Suppl 5): 551-554.
3. Lacourciere Y, Lefebvre J. Modulation of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 1995: 11(Suppl F): 33F-39F.
4. Diovan summary of product characteristics. Novartis, 1996.
5. Mann RD. Prescription event monitoring - Recent progress and future horizons. Br J Clin Pharmacol 1998; 46: 195-201.
6. WHO. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS/WHO, 1993.
7. Guidelines on the Practice of Ethical Committees in Medical Research Involving Human Subjects. Royal College of Physicians of London, August 1996.
8. Multicentre Research Ethics Committee. Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. Multi-Centre Research Ethics Committees Guidance Notes 2000. Appendix C: 19.
9. Freemantle SN et al. The incidence of the most commonly reported events with 40 newly marketed drugs - Study by Prescription-Event Monitoring. Pharmacoepidemiol Drug Safety 1997; 6(Suppl 1): 1-8.
10. Templeton L et al. Surveying general practitioners: Does a low response rate matter? Br J Gen Pract 1997; 47: 91-94.
11. McAvoy BR, Kramer EFS. General practice postal surveys: A questionnaire too far? BMJ 1997; 313: 732-733.
12. Mann RD et al. Losartan: A study of pharmacovigilance data on 14522 patients. J Hum Hypertens 1999; 13: 551-557.
13. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Safety 1999; 21: 23-33.
14. Markham A, Goa KL. Valsartan: A review of its use in essential hypertension. Drugs 1997; 54: 299-311.
15. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II inhibitors: Cause or confounding? Br J Clin Pharmacol 1999; 47: 111-114.
16. Benz J et al. Valsartan, a new angiotensin II receptor antagonist: A double blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-107.
17. Israili ZH, Hall WD. Cough and angioneurotic oedema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
18. Heeley E et al. Prescription event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-1873.